Annual report on the state of the drugs problem in Europe launched (05.11.2009)
Today the EMCDDA launched its Annual report on the the state of the drugs problem in Europe. The report, available in 23 languages, provides the latest European data and commentary on the drug situation across the 27 EU Member States, Croatia, Turkey and Norway. Individual chapters dedicated to specific drugs are complemented by updates on drug-related infectious diseases and deaths, new drugs and emerging trends and the legal, political, social and health responses to Europe’s drugs problem. Full details including news releases and supporting material on the event can be found on the Annual report event page.
Related links
Cocaine and heroin maintain a firm hold on Europe’s drug scene (05.11.2009)
Cocaine and heroin are maintaining a firm hold on Europe’s drug scene and there is little to suggest any improvement regarding their use. Polydrug use is also a major concern, as the range of available substances grows and drug-taking repertoires become increasingly complex. But on a more positive note, new data confirm a continued fall in cannabis use, particularly among young people. These were among the key points stressed by the EMCDDA as it launched its Annual report 2009: the state of the drugs problem in Europe on 5 November in Brussels.
Read more in the Annual report 2009: highlights news release >>
Market innovation and sophistication challenge drug policies (05.11.2009)
Europe is faced with an increasingly complex and volatile synthetic drug market, says the EU drugs agency (EMCDDA). Suppliers are now ‘highly innovative’ in their production processes, product ranges and marketing and are demonstrating their ability to adapt quickly to controls. The ‘growing sophistication’ in marketing legal alternatives to illicit drugs (so-called ‘legal highs’) is also a worrying development. The difficulties of ‘hitting a moving target’ are described in the Annual report 2009: the state of the drugs problem in Europe, launched by the EMCDDA today in Brussels.
Read more in the New drugs: difficulties of ‘hitting a moving target’ news release >>
